Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy

CONCLUSIONS: In spite of the overdosage, this study confirms the efficiency of the BNT162b vaccine in eliciting a sustained antibody response as heterologous boost-vaccine in previously Oxford/AstraZeneca vaccinated recipients, as well as, prime-vaccine in COVID-19 infected receivers. Importantly, the humoral immune response of recipients was not proportional to the vaccine overdose. Nonetheless, we cannot portray a univocal effect of vaccine overdose concerning anti-SARS-CoV-2 antibody response because the values found were highly heterogeneous.PMID:34599902 | PMC:PMC8480142 | DOI:10.1016/j.cca.2021.09.022
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Source Type: research